first Western-trained Chinese scholars returning back to China. Since then, Dr. Shen has dedicated his entire life to the development of pharmaceutical industry in China and is renowned as one of the founding members of pharmaceutical industry.
During the Korean War, Dr. Shen took the task to lead the development of chloramphenicol, a badly-needed antibiotic for wounded Chinese soldiers. Under his guidance, a new synthetic method of chloramphenicol was developed. Within a few years, he achieved many significant technical innovations during the production processes, which significantly improved the manufacturing technique of chloramphenicol (Fig. 2) . In 1957, the new technique was successfully applied into large-scale production, which is hailed as an important milestone marking the beginning of modern pharmaceutical industry in China (Shen et al., 1950; Shen et al., 1958a, b, c, d, e, f) . In the 1950s and 1960s, he successfully synthesized crystalline Vitamin A acetate and Vitamin D 2 using domestic resources, supervised the synthesis and production of multiple steroid medicines such as hydrocortisone and dexamethasone (Shen et al., 1964a, b, c) , and accomplished the total synthesis of gestrinone, which laid a solid foundation for the industrial synthesis of 19-demethyl steroid drugs in China.
Towards the end of "Cultural Revolution" in 1973, Dr. Shen was reappointed as the Deputy Chief Engineer of Hunan Pharmaceutical Industry Research Institute. Shortly after that, he embarked on a new research topic based on effective constituents of Chinese Traditional Medicines (CTM). He demonstrated the unique chemical structure of agrimophol through the total synthesis method in 1976 (Shen et al., 1976a, b) , which was the active ingredient of an anti-tapeworm drug. In mid-1980s, he was appointed as the doctoral advisor in medicinal chemistry at Beijing Medical University (now part of Peking University) (Fig. 3) . He supervised the PhD candidates on the study of the total synthesis of Tanshinone IIA and Danshenxinkun B (1986-1988) Zhang and Shen, 1988) , and discovered the special pharmacological activities in some derivatives. In addition, his group also studied the methodology of total synthesis of erycibe alkaloid II (baogongteng A) and the analogues.
In late 1992, after his retirement, as the Deputy Chief Engineer of the State Pharmaceutical Administration of China and the Director General of the National Institutes of Pharmaceutical R&D, Dr. Shen established Beijing Jicai Pharmaceutical Research Institute. It was the first private pharmaceutical research institute in China, where he discovered a new crystal form of azithromycin. This discovery bypassed Pfizer's administrative restriction for azithromycin dehydrate in China. Later on, this product occupied the majority of domestic market share of Azithromycin with competitive price advantages, which substantially improved the access to the Chinese people. Additionally, his laboratory also overcame various technical challenges and developed for the first time in China various hard-to-synthesize specialty generics such as alfacalcidol, tibolone, budesonide, and tamsulosin.
With the development of China's science and technology, Dr. Shen became increasingly recognized in the international pharmaceutical field (Shen and Zhuang, 1984) . Given his distinguished contributions and international reputation in the field of medicinal chemistry, Dr. Shen was elected as the Communication Academician of France Medication Academy in 1983. In the 1980s, Dr. Shen attended many conferences held by the United Nations Industrial Development Organization and the World Health Organization. In 1987, he was appointed as a member of the World Health Organization's leading group working on the chemotherapy for the treatment of Malaria and played a critical role in introducing the anti-malarial medicine artemisinine which was developed in China to the world (Luo and Shen, 1987; Shen, 1991) . In 1988, he held the Directorship of Sino-Searle Foundation. In 1989, he was invited to join the editorial board of Medicinal Research Reviews and the Journal of Pharmaceutical Sciences.
Dr. Shen took the development of pharmaceutical science, the promotion of China's pharmaceutical industry and the health of people as his own duty, and went through an extraordinary way along the stormy development path of Chinese pharmaceutical industry. He advanced the basic research and key technologies of Chinese pharmaceutical science, advocated the translation and application of research achievements. With his distinguished achievements, Dr. Shen won two prizes of National New Product Award (1964) , five prizes of National Scientific Conference Award (1978) , the Third Class of National Invention Award (1982), and the Second Class for Beijing Science and Technology Progress Award (1999) . In 1999, he was elected as a member of the prestigious Chinese Academy of Engineering.
Dr. Shen witnessed and experienced China's poverty during his youth, and he felt deeply humiliated by the aggressions of foreign powers. This inspired him to work hard for China's rejuvenation and empower the nation with modern science. He summarized his research style as "subject driven by mission" and "starting with easy things, but never leave without digging in great depth". He always chose the research topics that are valuable to the development and progress of the country. He told his students many times, "As explorers of science, we must uphold the rule of self-reliance. Contributing to your country, rather than living on its support."
In 2001, at the age of 80, Dr. Shen gave up his quiet and comfortable life in Beijing and accepted the invitation to join Tianjin University with the hope of advancing pharmaceutical science and industry through education. He moved to Tianjin and co-founded the School of Pharmaceutical Science and Technology together with other colleagues at Tianjin University. During the school's early days, he always worked in the frontline regardless of his age and health. Everyone at Tianjin University was deeply inspired by his persevering spirit, which has become invaluable wealth to this institution.
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